JP5647998B2 - 免疫抑制剤としてのチアゾロピリミジン調節因子 - Google Patents

免疫抑制剤としてのチアゾロピリミジン調節因子 Download PDF

Info

Publication number
JP5647998B2
JP5647998B2 JP2011553476A JP2011553476A JP5647998B2 JP 5647998 B2 JP5647998 B2 JP 5647998B2 JP 2011553476 A JP2011553476 A JP 2011553476A JP 2011553476 A JP2011553476 A JP 2011553476A JP 5647998 B2 JP5647998 B2 JP 5647998B2
Authority
JP
Japan
Prior art keywords
amino
thiazolo
piperazin
pyrimidin
fluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011553476A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012520269A5 (cg-RX-API-DMAC7.html
JP2012520269A (ja
Inventor
ヘルデヴィユン、ピエト
ヨンゲ、スティーブン デ
ヨンゲ、スティーブン デ
− ジー ガオ、リン
− ジー ガオ、リン
− イエオン ヤン、ミ
− イエオン ヤン、ミ
− デロイドンク、バルト ファン
− デロイドンク、バルト ファン
ヨーゼフ アルベルト ヴァエル、マルク
ヨーゼフ アルベルト ヴァエル、マルク
リン、ユアン
フェルディナンド ヘルマン、ジャン
フェルディナンド ヘルマン、ジャン
ティエリー アンドレ ミシェル ルア、
ティエリー アンドレ ミシェル ルア、
Original Assignee
カトリーケ ユニバーシテイト ルーヴェン、ケー.ユー. ルーヴェン アール アンド ディー
カトリーケ ユニバーシテイト ルーヴェン、ケー.ユー. ルーヴェン アール アンド ディー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0904353A external-priority patent/GB0904353D0/en
Priority claimed from GB0904373A external-priority patent/GB0904373D0/en
Priority claimed from GB0911022A external-priority patent/GB0911022D0/en
Application filed by カトリーケ ユニバーシテイト ルーヴェン、ケー.ユー. ルーヴェン アール アンド ディー, カトリーケ ユニバーシテイト ルーヴェン、ケー.ユー. ルーヴェン アール アンド ディー filed Critical カトリーケ ユニバーシテイト ルーヴェン、ケー.ユー. ルーヴェン アール アンド ディー
Publication of JP2012520269A publication Critical patent/JP2012520269A/ja
Publication of JP2012520269A5 publication Critical patent/JP2012520269A5/ja
Application granted granted Critical
Publication of JP5647998B2 publication Critical patent/JP5647998B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011553476A 2009-03-13 2010-03-15 免疫抑制剤としてのチアゾロピリミジン調節因子 Expired - Fee Related JP5647998B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0904373.8 2009-03-13
GB0904353.0 2009-03-13
GB0904353A GB0904353D0 (en) 2009-03-13 2009-03-13 Novel thiazolopyrimidines
GB0904373A GB0904373D0 (en) 2009-03-13 2009-03-13 Novel thienopyrimidines
GB0911022A GB0911022D0 (en) 2009-06-26 2009-06-26 Novel purines
GB0911022.2 2009-06-26
PCT/EP2010/053318 WO2010103130A2 (en) 2009-03-13 2010-03-15 Novel bicyclic heterocycles

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014228403A Division JP6021880B2 (ja) 2009-03-13 2014-11-10 免疫抑制剤としてのチアゾロピリミジン調節因子

Publications (3)

Publication Number Publication Date
JP2012520269A JP2012520269A (ja) 2012-09-06
JP2012520269A5 JP2012520269A5 (cg-RX-API-DMAC7.html) 2013-05-02
JP5647998B2 true JP5647998B2 (ja) 2015-01-07

Family

ID=42181129

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011553476A Expired - Fee Related JP5647998B2 (ja) 2009-03-13 2010-03-15 免疫抑制剤としてのチアゾロピリミジン調節因子
JP2014228403A Expired - Fee Related JP6021880B2 (ja) 2009-03-13 2014-11-10 免疫抑制剤としてのチアゾロピリミジン調節因子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014228403A Expired - Fee Related JP6021880B2 (ja) 2009-03-13 2014-11-10 免疫抑制剤としてのチアゾロピリミジン調節因子

Country Status (6)

Country Link
US (2) US8901132B2 (cg-RX-API-DMAC7.html)
EP (2) EP2923734B1 (cg-RX-API-DMAC7.html)
JP (2) JP5647998B2 (cg-RX-API-DMAC7.html)
CA (2) CA2754890C (cg-RX-API-DMAC7.html)
ES (2) ES2543216T3 (cg-RX-API-DMAC7.html)
WO (1) WO2010103130A2 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ574028A (en) 2006-07-05 2010-10-29 Fibrotech Therapeutics Pty Ltd Tranilast analogues (substituted cinnamoyl anthranilate compounds) for treatment of conditions associated with firbrosis
EP2923734B1 (en) * 2009-03-13 2018-01-10 Katholieke Universiteit Leuven, K.U. Leuven R&D Purine analogues and their use as immunosuppressive agents
EP2947073B1 (en) * 2009-10-22 2019-04-03 Fibrotech Therapeutics Pty Ltd Fused ring analogues of anti-fibrotic agents
GB201012889D0 (en) * 2010-08-02 2010-09-15 Univ Leuven Kath Antiviral activity of novel bicyclic heterocycles
GB201015411D0 (en) * 2010-09-15 2010-10-27 Univ Leuven Kath Anti-cancer activity of novel bicyclic heterocycles
GB201114212D0 (en) 2011-08-18 2011-10-05 Ucb Pharma Sa Therapeutic agents
GB201115665D0 (en) 2011-09-09 2011-10-26 Univ Leuven Kath Autoimmune and inflammatory disorder therapy
US20130102601A1 (en) 2011-10-21 2013-04-25 F. Hoffmann-La Roche Ltd Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease
GB201119401D0 (en) 2011-11-10 2011-12-21 Ucb Pharma Sa Therapeutic agents
GB201217704D0 (en) 2012-10-03 2012-11-14 Ucb Pharma Sa Therapeutic agents
EA027752B1 (ru) * 2012-12-20 2017-08-31 Юсб Биофарма Спрл Терапевтически активные производные пиразолопиримидина
CN103044460B (zh) * 2013-01-30 2015-02-25 石家庄学院 3,5,7-三苯基-5H-噻唑并[3,2-a]嘧啶类衍生物及应用
EP2981289A1 (en) * 2013-04-05 2016-02-10 Polichem SA Use of pidotimod to treat inflammatory bowel disease
EP3049086A4 (en) * 2013-09-27 2017-02-22 Nimbus Iris, Inc. Irak inhibitors and uses thereof
TWI648281B (zh) 2013-10-17 2019-01-21 日商安斯泰來製藥股份有限公司 含硫二環式化合物
CN104892589A (zh) * 2014-03-07 2015-09-09 中国科学院上海药物研究所 一类杂环化合物、其制备方法和用途
GB201410817D0 (en) * 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R & D Therapeutic agents
US9822127B2 (en) * 2014-07-23 2017-11-21 The Board Of Trustees Of The Leland Stanford Junior University GAK modulators as antivirals
UY36390A (es) * 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
EA201790806A1 (ru) 2014-11-05 2017-11-30 Флексус Байосайенсиз, Инк. Иммунорегулирующие средства
GB201517263D0 (en) 2015-09-30 2015-11-11 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
GB201521767D0 (en) 2015-12-10 2016-01-27 Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R&D Therapeutic agents
EP3577103A1 (en) 2017-02-03 2019-12-11 Certa Therapeutics Pty Ltd. Anti-fibrotic compounds
TWI811428B (zh) 2018-08-21 2023-08-11 日商杏林製藥股份有限公司 雙環雜芳香環衍生物

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2512572A (en) 1950-06-20 Substituted pteridines and method
BE791242A (fr) * 1971-11-11 1973-05-10 Thomae Gmbh Dr K Nouvelles thiazolo(5,4-d)pyrimidines
US4127118B1 (en) 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
ZA857647B (en) * 1984-10-12 1986-05-28 Warner Lambert Co Purine derivatives
NZ225447A (en) * 1987-07-20 1991-12-23 Merck & Co Inc Piperazinyl derivatives of purine and purine isosteres and pharmaceutical compositions
US5057517A (en) * 1987-07-20 1991-10-15 Merck & Co., Inc. Piperazinyl derivatives of purines and isosteres thereof as hypoglycemic agents
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
JP2001097979A (ja) * 1999-07-28 2001-04-10 Takeda Chem Ind Ltd 縮合複素環化合物、その製造法および用途
US6331547B1 (en) 1999-08-18 2001-12-18 American Home Products Corporation Water soluble SDZ RAD esters
DE60101372T2 (de) * 2000-02-11 2004-10-14 Astrazeneca Ab Pyrimidinverbindungen und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
JP2004028376A (ja) 2002-06-21 2004-01-29 Hino Motors Ltd Egrクーラ
AU2003284142A1 (en) * 2002-10-15 2004-05-04 Synta Pharmaceuticals Corp Aromatic bicyclic heterocyles to modulate 1L-12 production
AU2003302657B8 (en) * 2002-12-04 2009-12-03 Eisai R&D Management Co., Ltd. Fused 1,3-dihydroimidazole ring compounds
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
CN1823071B (zh) 2003-06-11 2012-12-19 润生有限公司 用作钾通道抑制剂的噻吩并嘧啶衍生物
DE10348023A1 (de) * 2003-10-15 2005-05-19 Imtm Gmbh Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
JPWO2005095419A1 (ja) 2004-04-01 2008-02-21 武田薬品工業株式会社 チアゾロピリミジン誘導体
GB0407723D0 (en) * 2004-04-05 2004-05-12 Novartis Ag Organic compounds
US7576080B2 (en) 2004-12-23 2009-08-18 Memory Pharmaceuticals Corporation Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors
FR2880626B1 (fr) * 2005-01-13 2008-04-18 Aventis Pharma Sa Derives de la purine, compositions les contenant et utilisation
CA2595882A1 (en) * 2005-01-26 2006-08-03 Pharmacia & Upjohn Company Llc Thieno [2,3-d] pyrimidine compounds as inhibitors of adp-mediated platelets aggregation
CN101248074A (zh) 2005-07-01 2008-08-20 日本化学医药株式会社 黄嘌呤氧化酶抑制剂
GB0526246D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
US20080108611A1 (en) 2006-01-19 2008-05-08 Battista Kathleen A Substituted thienopyrimidine kinase inhibitors
KR100846988B1 (ko) 2006-03-06 2008-07-16 제일약품주식회사 신규한 티에노피리미딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 함유하는 약학조성물
AU2007243466B2 (en) * 2006-04-26 2012-01-19 F. Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
KR101077295B1 (ko) * 2006-05-18 2011-10-26 에프. 호프만-라 로슈 아게 아데노신 a2b 수용체 길항물질로서의 티아졸로-피라미딘/피리딘 우레아 유도체
US20080004253A1 (en) * 2006-06-30 2008-01-03 Bryan James Branstetter Thiazolopyrimidine modulators of TRPV1
ME02789B (me) 2006-08-08 2011-06-30 Millennium Pharm Inc Jedinjenja heteroarila korisna kao inhibitori e1 aktivirajućih enzima
WO2008057402A2 (en) * 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof
KR20100014271A (ko) 2006-11-16 2010-02-10 파마코페이아, 엘엘씨. 면역 억제를 위한 7-치환된 퓨린 유도체
WO2008059368A2 (en) 2006-11-17 2008-05-22 Pfizer Products Inc. Fused 2-amino pyrimidine compounds and their use for the treatment of cancer
CA2671845C (en) * 2006-12-07 2015-03-24 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and methods of use
BRPI0806811A2 (pt) 2007-01-23 2011-09-13 Palau Pharma Sa derivados de purina
CA2676138A1 (en) 2007-01-26 2008-08-07 Irm Llc Compounds and compositions as kinase inhibitors
WO2008135232A1 (en) 2007-05-02 2008-11-13 Riccardo Cortese Use and compositions of purine derivatives for the treatment of proliferative disorders
ATE510841T1 (de) * 2007-06-12 2011-06-15 Hoffmann La Roche Thiazoliopyrimidine und ihre verwendung als hemmer der phosphatidylinositol-3 kinase
EP2170888B1 (en) 2007-06-29 2015-04-22 Gilead Sciences, Inc. Purine derivatives and their use as modulators of toll-like receptor 7
WO2009013545A2 (en) * 2007-07-26 2009-01-29 Astrazeneca Ab Chemical compounds
WO2009027732A1 (en) * 2007-08-24 2009-03-05 Astrazeneca Ab 5-6-bicyclic heteroaromatic compounds with antibacterial activity
CN101932587A (zh) * 2007-09-24 2010-12-29 吉宁特有限公司 噻唑并嘧啶pi3k抑制剂化合物及使用方法
UA104010C2 (en) * 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
EP2923734B1 (en) * 2009-03-13 2018-01-10 Katholieke Universiteit Leuven, K.U. Leuven R&D Purine analogues and their use as immunosuppressive agents
AR080711A1 (es) * 2010-03-31 2012-05-02 Lilly Co Eli Compuesto de piperazin-purina composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento o prevencion del dolor

Also Published As

Publication number Publication date
ES2665277T3 (es) 2018-04-25
CA2754890C (en) 2018-01-16
CA2754890A1 (en) 2010-09-16
US8901132B2 (en) 2014-12-02
US20150038494A1 (en) 2015-02-05
WO2010103130A2 (en) 2010-09-16
US20120046278A1 (en) 2012-02-23
EP2405973A2 (en) 2012-01-18
JP2012520269A (ja) 2012-09-06
CA2987743A1 (en) 2010-09-16
US9221822B2 (en) 2015-12-29
EP2923734B1 (en) 2018-01-10
JP2015028088A (ja) 2015-02-12
ES2543216T3 (es) 2015-08-17
JP6021880B2 (ja) 2016-11-09
EP2923734A1 (en) 2015-09-30
WO2010103130A3 (en) 2010-12-23
EP2405973B1 (en) 2015-04-22

Similar Documents

Publication Publication Date Title
JP6021880B2 (ja) 免疫抑制剤としてのチアゾロピリミジン調節因子
US9573966B2 (en) Anti-cancer activity of novel bicyclic heterocycles
US9730944B2 (en) Antiviral activity of novel bicyclic heterocycles
US8232278B2 (en) Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C
US20090036430A1 (en) Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
US20080004285A1 (en) Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
JP2011529918A (ja) Jak3阻害剤としてのピペリジン誘導体
JP2022526854A (ja) ホスファチジルイノシトール3-キナーゼ阻害剤
AU2011213198A1 (en) Pyrrolo [ 2,3-d] pyrimidine urea compounds as JAK inhibitors
JP2008526704A (ja) ピリド(3,2−d)ピリミジンおよび医療処置に有用な医薬組成物
JPWO2002019975A1 (ja) 育毛剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130312

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130312

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140916

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141009

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141110

R150 Certificate of patent or registration of utility model

Ref document number: 5647998

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees